Xiaolei Li

发表

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer

M. Brock, Q. Mei, M. Guo, 2018, International journal of cancer.